The DILI‐sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation

The drug‐induced liver injury (DILI)‐sim Initiative is a public‐private partnership involving scientists from industry, academia, and the US Food and Drug Administration (FDA). The Initiative uses quantitative systems toxicology (QST) to build and refine a model (DILIsym) capable of understanding and predicting liver safety liabilities in new drug candidates and to optimize interpretation of liver safety biomarkers used in clinical studies. Insights gained to date include the observation that most dose‐dependent hepatotoxicity can be accounted for by combinations of just three mechanisms (oxidative stress, interference with mitochondrial respiration, and alterations in bile acid homeostasis) and the importance of noncompetitive inhibition of bile acid transporters. The effort has also provided novel insight into species and interpatient differences in susceptibility, structure‐activity relationships, and the role of nonimmune mechanisms in delayed idiosyncratic hepatotoxicity. The model is increasingly used to evaluate new drug candidates and several clinical trials are underway that will test the model's ability to prospectively predict liver safety. With more refinement, in the future, it may be possible to use the DILIsym predictions to justify reduction in the size of some clinical trials. The mature model could also potentially assist physicians in managing the liver safety of their patients as well as aid in the diagnosis of DILI.

[1]  S. Siler,et al.  Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials , 2017, Clinical pharmacology and therapeutics.

[2]  P. Watkins,et al.  Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[4]  Hugh A. Barton,et al.  Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development , 2016 .

[5]  John M. Burke,et al.  Quantitative systems toxicology , 2017, Current opinion in toxicology.

[6]  D. Day,et al.  Histopathological changes in the liver following a paracetamol overdose: Correlation with clinical and biochemical parameters , 1975, The Journal of pathology.

[7]  Y. Yang,et al.  Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury , 2016, CPT: pharmacometrics & systems pharmacology.

[8]  C. Battista,et al.  Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters , 2017, Clinical pharmacology and therapeutics.

[9]  Paul B Watkins,et al.  Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. , 2014, Biopharmaceutics & drug disposition.

[10]  P. Watkins,et al.  Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) , 2011, Drug safety.

[11]  P. Watkins,et al.  The transformation in biomarker detection and management of drug‐induced liver injury , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[12]  Leslie Z Benet,et al.  Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  P. Watkins,et al.  Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa) , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  A. D. Rodrigues,et al.  Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective , 2018, Clinical pharmacology and therapeutics.

[15]  J. Cai,et al.  Toll-like receptors and radiation protection. , 2018, European review for medical and pharmacological sciences.

[16]  D. Abernethy,et al.  Application of Systems Pharmacology to Explore Mechanisms of Hepatotoxicity , 2014, Clinical pharmacology and therapeutics.

[17]  Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.

[18]  A. Rosenberg,et al.  Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[19]  Jerome T. Mettetal,et al.  Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  P B Watkins,et al.  Drug Safety Sciences and the Bottleneck in Drug Development , 2011, Clinical pharmacology and therapeutics.

[21]  Y. Dragan,et al.  Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  H. Barnhart,et al.  Death and liver transplantation within 2 years of onset of drug‐induced liver injury , 2017, Hepatology.

[23]  Melvin E. Andersen,et al.  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  N. Kaplowitz,et al.  Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis , 2017, International journal of molecular sciences.

[25]  M. Mosedale,et al.  Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management , 2017, Clinical pharmacology and therapeutics.

[26]  P. Watkins,et al.  Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology Modeling , 2018, Clinical and translational science.

[27]  P. Watkins,et al.  Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses , 2017, Gene regulation and systems biology.

[28]  P. Watkins,et al.  A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial , 2014, CPT: pharmacometrics & systems pharmacology.

[29]  P. Watkins,et al.  Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI , 2014, CPT: pharmacometrics & systems pharmacology.

[30]  The publishing and patenting strategies of successful university spinoffs in the biopharmaceutical industry. , 2017, Drug discovery today.

[31]  Paul B Watkins,et al.  Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity , 2014, Clinical pharmacology and therapeutics.

[32]  Paul B Watkins,et al.  Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. , 2014, Toxicology letters.

[33]  R. Roth,et al.  Neutrophil- and Glutathione-Mediated Hepatotoxicity of α-Naphthylisothiocyanate , 1997 .

[34]  K. He,et al.  Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury. , 2015, Chemical research in toxicology.

[35]  Hugh A. Barton,et al.  Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury , 2014, Front. Pharmacol..

[36]  K. Brouwer,et al.  Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[37]  Melvin E. Andersen,et al.  An Analysis of N-Acetylcysteine Treatment for Acetaminophen Overdose Using a Systems Model of Drug-Induced Liver Injury , 2012, Journal of Pharmacology and Experimental Therapeutics.

[38]  Paul B Watkins,et al.  In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials , 2018, Experimental biology and medicine.

[39]  Paul B Watkins,et al.  The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. , 2017, Drug metabolism and pharmacokinetics.